• The Korean Journal of Physiology and Pharmacology
• /
• 제7권6호
• /
• pp.325-331
• /
• 2003

3-Nitropropionic acid (3-NP) inhibits electron transport in mitochondria, leading to a metabolic failure. In order to elucidate the mechanism underlying this toxicity, we examined a few biochemical changes possibly involved in the process, such as metabolic inhibition, generation of reactive oxygen species (ROS), DNA strand breakage, and activation of Poly(ADP-ribose) polymerase (PARP). Exposure of SK-N-BE(2)C neuroblastoma cells to 3-NP for 48 h caused actual cell death, while inhibition of mitochondrial function was readily observed when exposed for 24 h to low concentrations (0.2${\sim}$2 mM) of 3-NP. The earliest biochemical change detected with low concentration of 3-NP was an accumulation of ROS (4 h after 3-NP exposure) followed by degradation of DNA. PARP activation by damaged DNA was also detectable, but at a later time. The accumulation of ROS and DNA strand breakage were suppressed by the addition of glutathione or N-acetyl-L-cysteine (NAC), which also partially restored mitochondrial function and cell viability. In addition, inhibition of PARP also reduced the 3-NP-induced DNA strand breakage and cytotoxicity. These results suggest that oxidative stress and activation of PARP are the major factors in 3-NP-induced cytotoxicity, and that the inhibition of these factors may be useful in protecting neuroblastoma cells from 3-NP-induced toxicity.

• Korean Chemical Engineering Research
• /
• 제49권5호
• /
• pp.633-638
• /
• 2011

Mn이 치환된 헥사알루미네이트 촉매인 $LaMnAl_{11}O_{19}$, $BaMnAl_{11}O_{19}$, $SrMnAl_{11}O_{19}$을 $(NH_4)_2CO_3$ 공침법을 이용하여, $1,200^{\circ}C$ 5시간 소성을 통해 제조하였다. X-선 회절, 질소흡착을 통해 촉매의 결정구조와 비표면적을 분석한 결과, 결정 격자 내 거울면에 La이 존재하는 $LaMnAl_{11}O_{19}$이 $BaMnAl_{11}O_{19}$과 $SrMnAl_{11}O_{19}$보다 우수한 헥사알루미네이트 결정 구조를 가지는 동시에 13 $m^2/g$의 높은 비표면적을 가지고 있었다. 또한 SEM 분석을 통해 $LaMnAl_{11}O_{19}$이 특유의 판상구조가 잘 발달함을 확인하였다. 메탄 연소 활성은 다음과 같은 차례로 증가하였고: $LaMnAl_{11}O_{19}$ > $SrMnAl_{11}O_{19}$ > $BaMnAl_{11}O_{19}$. 메탄 연소 활성은 비표면적에 의존하였다. $LaMnAl_{11}O_{19}$에 60 wt%의 $CeO_2$를 첨가하고 $700^{\circ}C$의 저온에서 소성한 경우 $700^{\circ}C$의 저온에서 100% 전환율에 도달함으로써 ceria 첨가에 의한 메탄 연소 개선 효과를 확인할 수 있었으며, 이 촉매가 저온 및 중온 영역의 메탄 연소 촉매로 활용될 수 있음을 확인하였다. 그러나, 이 촉매의 경우 $1,200^{\circ}C$의 고온에서 5시간 소성한 후에는 ceria입자 크기의 증가로 인해 메탄의 연소 활성 개선 효과를 잃게됨으로 고온용 연소 촉매로서의 사용은 한계가 있음을 확인하였다.

• Clinical and Experimental Reproductive Medicine
• /
• 제32권4호
• /
• pp.315-324
• /
• 2005

Objectives: To compare the efficacy of GnRH antagonist multiple dose protocol (MDP) with that of GnRH agonist long protocol (LP) in controlled ovarian hyperstimulation for in vitro fertilization in patients with high basal FSH (follicle stimulating hormone) level or old age, a retrospective analysis was done. Methods: Two hundred ninety four infertile women (328 cycles) who were older than 41 years of age or had elevated basal FSH level (> 8.5 mIU/mL) were enrolled in this study. The patients had undergone IVF-ET after controlled ovarian hyperstimulation using GnRH antagonist multiple dose protocol (n=108, 118 cycles) or GnRH agonist long protocol (n=186, 210 cycles). The main outcome measurements were cycle cancellation rate, consumption of gonadotropins, the number of follicles recruited and total oocytes retrieved. The number of fertilized oocytes and transferred embryos, the clinical pregnancy rates, and the implantation rates were also reviewed. And enrolled patients were divided into three groups according to their age and basal FSH levels; Group A - those who were older than 41 years of age, Group B - those with elevated basal FSH level (> 8.5 mIU/mL) and Group C - those who were older than 41 years of age and with elevated basal FSH level (> 8.5 mIU/mL). Poor responders were classified as patients who had less than 4 retrieved oocytes, or those with $E_2$ level <500 pg/mL on the day of hCG injection or those who required more than 45 ampules of exogenous gonadotropin for stimulation. Results: The cancellation rate was lower in the GnRH antagonist group than in GnRH agonist group, but not statistically significant (6.8% vs. 9.5%, p=NS). The amount of used gonadotropins was significantly lower in GnRH antagonist group than in agonist group ($34.8{\pm}11.3$ ampules vs. $44.1{\pm}13.4$ ampules, p<0.001). The number of follicles > 14 mm in diameter was significantly higher in agonist group than in antagonist group ($6.7{\pm}4.6$ vs. $5.0{\pm}3.4$, p<0.01). But, there were no significant differences in clinical pregnancy rate (24.5% in antagonist group vs. 27.4% in agonist group, p=NS) and implantation rate (11.4% in antagonist group vs. 12.0% in agonist group, p=NS) between two groups. Mean number of retrieved oocytes was significantly higher in GnRH agonist LP group than in GnRH antagonist MDP group ($5.4{\pm}3.5$ vs. $6.6{\pm}5.0$, p<0.0001). But, the number of mature and fertilized oocytes, and the number of good quality (grade I and II) and transferred embryos were not different between two groups. In each group A, B, and C, the rate of poor response did not differ according to stimulation protocols. Conclusions: In conclusion, for infertile women expected poor ovarian response such as who are old age or has elevated basal FSH level, a protocol including a controlled ovarian hyperstimulation using GnRH antagonist appears at least as effective as that using a GnRH agonist, and may offer the advantage of reducing gonadotropin consumption and treatment period. However, much work remains to be done in optimizing the GnRH antagonist protocols and individualizing these to different cycle characteristics.